Wall Street analysts expect NuCana PLC (NASDAQ:NCNA) to announce ($0.24) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for NuCana’s earnings. The lowest EPS estimate is ($0.33) and the highest is ($0.18). The company is expected to issue its next quarterly earnings report on Monday, January 1st.
Zacks’ earnings per share averages are an average based on a survey of analysts that cover NuCana.
A number of equities analysts have weighed in on the stock. Zacks Investment Research raised shares of NuCana from a “sell” rating to a “hold” rating in a research note on Wednesday, May 23rd. Cowen reaffirmed a “buy” rating on shares of NuCana in a research note on Thursday, May 24th. Finally, ValuEngine raised shares of NuCana from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $21.00.
Institutional investors have recently added to or reduced their stakes in the company. Alps Advisors Inc. acquired a new stake in shares of NuCana in the fourth quarter worth $357,000. Asymmetry Capital Management L.P. acquired a new stake in shares of NuCana in the first quarter worth $765,000. UBS Asset Management Americas Inc. increased its position in shares of NuCana by 4.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 464,600 shares of the company’s stock worth $4,697,000 after acquiring an additional 19,800 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of NuCana by 40.1% in the fourth quarter. Alliancebernstein L.P. now owns 910,358 shares of the company’s stock worth $9,204,000 after acquiring an additional 260,358 shares in the last quarter. Finally, Baillie Gifford & Co. increased its position in shares of NuCana by 16.6% in the first quarter. Baillie Gifford & Co. now owns 641,120 shares of the company’s stock worth $12,130,000 after acquiring an additional 91,120 shares in the last quarter. 46.34% of the stock is owned by institutional investors.
NuCana opened at $29.84 on Thursday, Marketbeat Ratings reports. The company has a market cap of $884.35 million and a price-to-earnings ratio of -28.15. NuCana has a fifty-two week low of $9.32 and a fifty-two week high of $30.41.
NuCana Company Profile
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.
Get a free copy of the Zacks research report on NuCana (NCNA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.